Avilex Pharma is a bio-pharmaceutical company developing dimeric peptides, which targets postsynaptic density protein 95 (PSD95) for the treatment of ischemic stroke.
Avilex is a spin out from the University of Copenhagen, founded by Prof. Kristian Strmgaard and Assis. Prof. Anders Bach of the Department of Drug Design and Pharmacology, with investment from Novo Seeds (part of Novo A/S) and Wellcome Trust.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/avidity-nanomedicines” connections=”true” suffix=””]
In June 2015, Avilex received a 18 Mn DKK (2.4 Mn EUR) Translation Award from the Wellcome Trust to fund the development of a novel drug candidate for acute treatment of ischemic stroke. In addition to this award, Avilex has raised additional equity funding of 10 Mn DKK (1.35 Mn EUR) from Novo Seeds, the early stage investment arm of Novo A/S.
Recover your password.
A password will be e-mailed to you.